



Middle East Journal of Therapeutic

Nutrition and Complementary Medicine

H. pylori Eradication and Strict Diet Regimen's Synergetic Effect on Glycemic State in Type Two Diabetics on Insulin Therapy

Ehab Kamal¹, Maha M. Saber¹, Eitedal Daoud¹, Hanan Ezelarab², Hazem El Hariri³, Neveen A. Helmy⁴ and Mohamed AbdAllah¹

1 Complementary medicine department, Medical research division, National research center; 2 Public health department, Ain shams university; 3 Community department, Medical research division, National research center; 4 Clinical and chemical pathology, medical research division, National research center

HELICOBACTER pylori (*H. pylori*) infection affects nearly 50% of the human population reaching an incidence rate of about 70% in developing countries. Egypt is one of the highest endemic areas for this infection. *H. pylori* infection is associated with gastro-intestinal and extra gastric diseases. Type two diabetes mellitus (T2DM) is the prevalent type of DM reaching about 90%, WHO predicting the number of patients to be 438 million by year 2030. Inflammation is the playing factor in the etiology of DM and insulin resistance. *H. pylori* could be the source of infection. This research aimed to detect the effect of *H. pylori* eradication on glycemic control in T2DM on insulin therapy with and without diet planning. This is a randomized controlled clinical trial involving 68 well known T2DM patients on insulin therapy proved *H. pylori* positive by detection of antigens using ELISA kit (Epitope diagnostics. USA). In the stool. those patients were recruited from the outpatient clinics of the National Research Centre. The patients were randomized into 4 equal groups; Group 1 (M) received their routine medical treatment only, group 2 (MD) received medical treatment and individualized planned dietary regimen, group 3 (MH) received medical and anti-*H. pylori* treatment while group 4 (MHD) received medical, anti-*H. pylori* treatment and dietary regimen. Initial baseline evaluation included: diabetes panel, lipid profile, liver enzymes, renal functions and BMI which is repeated at the end of 6 months follow up. The results showed a significant decrease of mean FBG, PPBG and HbA1c levels at the end of 6 months intervention from baseline levels in the 4 groups, however the mean difference increased from group 1 to group 4. Mean BMI and Uric acid significantly decreased in all groups except group-M. Cholesterol and triglycerides significantly decreased in all groups. Non-statistically significant changes regarding ALT, AST and serum creatinine were observed in all groups. Based on these results it is recommended to use the combined regimen of medical treatment together with anti *H. pylori* and diet control for better glycemic and lipid profile control in patients with type II diabetes who depends on insulin therapy.

Keywords: *H. pylori*, diabetes, insulin, diet

Introduction

H. pylori infection is caused by a Gram-negative bacterium that mainly causes gastric disorders ranging from gastritis up to peptic ulcer disease (10-15%) and MALT lymphoma (less than 1%) of the total infected population with a high

prevalence rate reaching about 50% of the world population affecting the developing countries more frequent than the developed countries (Horiki et al., 2009). *H. pylori* infection is commonly transmitted either by the oral or the feco- oral route (Fallone, 2000).

Correspondent author: Ehab Kamal, Complementary medicine department, Medical research division, National research centre, El-Bohouth Street, Dokki, Cairo, Egypt, email: ehabkamal2011@hotmail.com

DOI: 10.21608/mejt.2021.14867.1006

©2021 National Information and Documentation Center (NIDOC)

H. pylori infection causes chronic active gastritis infiltrating the lamina propria by inflammatory cells; neutrophils, macrophages, T and B lymphocytes and mast cells. Mast cells are responsible for the host immune reaction with great evidence that *H. pylori* is not invading the gastric mucosa but taking a niche within the mucosa to be protected from the gastric secretions. After mucosal contact with the *H. pylori* the release of chemotactic factors could recall the inflammatory cells within the infected area. Interferon-gamma inducible protein-10 (IP-10) and the monokine-induced by interferon-gamma (MIG) are released by the endothelial cells and the mononuclear cells of the host infected by chronic *H. pylori* gastritis. Another hypothesis that *H. pylori* itself may recall immune cells from afar by its own membrane molecules such as urea or lipopolysaccharide (LPS) (HSU *et al.*, 2014).

The sequela of this infection is variable from mild to severe gastritis about 10-15% will develop gastric ulcers while less than 1% will develop malignancy in the form of gastric adenocarcinoma (Paziak-Domańska *et al.*, 2000). The difference in the outcome of the infection is mostly contributed to variations in the lifestyles, socioeconomic levels and diet of the host population in addition to the presence of CagA strains (Bruewer *et al.*, 2003).

The relation of *H. pylori* infection and extra-gastric diseases is recently detected. The relation of *H. pylori* infection and iron deficiency anemia either by erosive gastritis (Papagiannakis *et al.*, 2013) or decrease the acid production due to gastric atrophy (El-Eshrawy *et al.*, 2011) or due to the presence of CagA protein of *H. pylori* which share in iron acquisition from interstitial holotransferrin (Xu *et al.*, 2017).

Molecular mimicry may be responsible for the correlation between *H. pylori* infection and Immune thrombocytopenic purpura (ITP) it is claimed that the monoclonal antibodies generated against *H. pylori* react with GP IIb/IIIa identified on the platelet surface (Azuma *et al.*, 2002).

There was an association between *H. pylori* infection and Diabetes mellitus (DM), insulin resistance and poor glycemic control (Choi *et al.*, 2016). The association of *H. pylori* infection and the coronary artery disease is also documented where several studies related the infection with acute coronary syndrome and risk of myocardial infarction (Zojaji *et al.*, 2013).

The relationship between *H. pylori* infection and obesity was controversial where some studies documented this relation (Dai *et al.*, 2015) while other studies deny the relation (Horikawa *et al.*, 2014).

Patients and Methods

Study design

Enrolment of 68 diabetic patients who have been proven to be *H. pylori* positive by stool antigen test by ELISA kit (Epitope diagnostics. USA). Study setting were at the outpatient clinics of the National Research Centre, Egypt. Study subjects were randomly divided into 4 groups; group 1: received their standard medical treatment for diabetes (M), group 2: received standard medical treatment for diabetes and individualized diet regimen (MD), group 3: received standard medical treatment for diabetes and drug treatment of *H. pylori* (MH) and group 4: received standard treatment for diabetes and drug treatment of *H. pylori* and individualized diet regimen (SHD).

Inclusion criteria

- 1- Adults, both sexes have been involved.
- 2- Type II diabetics on insulin therapy.
- 3- *H. pylori* positive cases with stool antigen test or urea breath test.
- 4- Regularly attend the NRC outpatient clinic.

Exclusion criteria

- 1- Type I diabetic patients.
- 2- History of recent anti *H. pylori* treatment within the last 6 months with the same prescribed regimen.

Study details

For all involved patients, 1) detailed medical and dietary history was taken, 2) revised appropriate dosage of their standard medical treatment for diabetes was done.

For the first group: after termination of the study (6 months intervention), they were offered treatment for *H. pylori* and detailed individualized diet regimen.

For the second group: they received in addition a detailed individualized diet regimen. After termination of the study, treatment for *H. pylori* was provided.

For the third group: anti-*H. pylori* treatment was prescribed. After termination of the study, they were offered detailed individualized diet regimen.

For the fourth group: anti-H. pylori treatment was prescribed and detailed individualized diet regimen.

History taking was documented including both medical history and dietary history anthropometric measures was undertaken in addition to clinical examination (Westat Inc., 1988).

A detailed individualized diet regimen was applied according to his requirements and the available resources. Dietary calories were evaluated and each patient was asked to follow his/her dietary plan as follows:

Calories intake plan was discussed individually for each patient according to Eating patterns and meal planning. American Diabetes Association, 2019.

The treatment regimen for the H. pylori as follows:

Non bismuth quadruple sequential therapy as a treatment of H. pylori in the form of:

PPI plus amoxicillin for 7 days followed by PPI plus clarithromycin and metronidazole for another 7 days

The following laboratory investigations were done as an initial evaluation of each patient:

FBG, PPG, HBA1C, Lipid profile (cholesterol, triglyceride), liver enzymes, creatinine level, serum uric acid using Olympus Au-800 Automated Chemistry Analyzer (Olympus, Japan).

Randomization and concealment

Following enrollment, we randomly assigned 64 patients to one of the 4 study groups according to the time of enrollment. Randomization was by using a computer-generated random numbers table. The assigned treatment was written on a card and sealed in opaque envelopes consecutively numbered. These envelopes opened just immediately before the procedure.

Study patients were planned to have every 2 weeks visit for follow up the medical treatment and the strict follow up of the dietary plan.

Of the received patients whom were about 85 patients, 81 patients accepted to be enrolled, 68 patients have been proven to be H. pylori positive by ELISA (Epitope diagnostics. USA) reaching a percentage of 83.9% of the total patients received.

After explanation of the study and the plan of treatment to every patient and signing the consent by the patient the study was initiated individually.

Results

Group-M: Cases received medical treatment only.

Group-MD: Cases received medical treatment and dietary regimen.

Group-MH: Cases received medical and anti-H.

Baseline characteristics and measures between study groups showed none significant difference regarding age, sex, BMI, diabetes panel, liver enzymes, creatinine, uric acid or lipid profile (table 1).

A significant reduction of mean value of BMI (6 month- baseline levels) was observed in all groups except group-M. Highest difference was found in group-MHD, followed by group-MH& then group-MD.

Diabetes panel (FBG, PPBG and HbA1c), showed significant reduction of mean values, however the highest difference was in group-MHD.

No significant difference between the studied groups regarding ALT and AST month-6 after intervention and baseline values.

Mean cholesterol and triglycerides month-6 after intervention from baseline showed significance difference in each of the studied groups.

Regarding uric acid, a significant reduction of mean value (6 month- baseline levels) was observed in all groups except group-M. Highest difference was found in group-MHD, followed by group-MH& then group-MD.

Statistical methods

The collected data were coded, tabulated, and statistically analyzed using IBM SPSS statistics (Statistical Package for Social Sciences) software version 18.0, IBM Corp., Chicago, USA, 2009.

Descriptive statistics were done for quantitative data as minimum & maximum of the range as well as mean \pm SD (standard deviation) for quantitative normally distributed data, while it was done for qualitative data as number and percentage.

Inferential analyses were done for quantitative variables using Shapiro-Wilk test for normality testing, paired t-test in cases of two dependent groups and ANOVA test with post hoc Tukey test for more than two independent groups. In qualitative data, inferential analyses for independent variables were done using Chi square test for differences between proportions. The level of significance was taken at P value $<$ 0.050 is significant, otherwise is non-significant.

TABLE 1. Baseline characteristics and measures of studied Type2DM on insulin therapy .

Variable	Statistics	Group-M	Group-MD	Group-MH	Group-MHD	Sig. P value
Age (years)	Mean ± SD (range)	50.3±7.5 (37.0–62.0)	50.4±6.8 (34.0–64.0)	51.6±5.4 (44.0–60.0)	47.7±8.6 (35.0–61.0)	0.445
Sex Male Female	(No %) (No %)	5 (29.4%) 12 (70.6%)	3 (17.6%) 14 (82.4%)	7 (41.2%) 10 (58.8%)	7 (41.2%) 10 (58.8%)	0.398
BMI (kg/m ²)	Mean±SD (range)	27.6±2.7 (24.0-32.0)	27.9±2.1 (25.0 - 32.0)	27.1±2.4 (23.0—33.0)	28.2±2.5 (22.0-32.0)	0.611
FBG (mg/dL)	Mean±SD (range)	180.1±41.1 (110- 240.0)	174.4±48.8 (100.0-270.0)	187.1±65.5 (105 -370)	195.0±46.4 (130 -275)	0.222
PPBG (mg/dL)	Mean±SD (range)	242.2±103.2 (120 --425)	240.2±97.4 (110 -472)	261.6±99.1 (125 - 470)	274.7±104.2 (140 -450)	0.717
HbA1c	Mean±SD (range)	7.9±1.8 (5.0 -11.0)	7.9±1.8 (5.5 -13.0)	8.5±2.1 (5.8 -12.5)	9.2±2.3 (6.0 – 13.0)	0.199
ALT (IU/mL)	Mean±SD (range)	33.2±11.0 (20 - 60)	34.4±12.3 (18 -55)	35.3±11.2 (22 -55)	37.2±10.8 (20.0 -58.0)	0.771
AST (IU/mL)	Mean±SD (range)	29.5±9.5 (18.0 -50.0)	30.4±12.4 (17.0-62.0)	29.1±7.8 (17 -40.0)	35.2±11.6 (20.0 -60.0)	0.303
Creatinine (mg/dL)	Mean±SD (range)	0.97±0.34 (0.40 -1.8)	0.98±0.35 (0.5 -1.8)	1.04±0.21 (0.7 -1.4)	1.12±0.36 (0.5 -2.0)	0.530
Uric acid (mg/dl)	Mean±SD (range)	5.6±1.9 (2.9 -9.0)	5.5±1.7 (3.5 -9.0)	6.1±1.6 (3.5-8.5)	5.2±0.8 (4.0- 7.0)	0.392
t.Cholesterol (mg/dL)	Mean±SD (range)	212.6±64.4 (140 -350)	231.8±58.1 (150 -350)	208.5±74.5 (140 -400)	242.9±53.5 (150 -350)	0.348
Triglycerides (mg/dL)	Mean±SD (range)	172.6±51.2 (100 - 300)	178.5±41.5 (110 -255)	159.7±65.6 (100 -350)	182.4±53.9 (90 - 300)	0.632




Fig. 1. Flow chart shows study subjects enrollment .

TABLE 2. Mean difference 6 months after intervention from baseline of body mass index, blood glucose levels, liver, renal functions and lipid profile of studied Type2DM on insulin therapy.

Parameters	Group-M	Group-MH	Group-MD	Group-MHD	Sig. ^ P value
BMI (kg/m ²) Mean±SD P value	-0.2±0.8 0.390	4±0.5 0.010*	-0.4±0.7 0.022*	-0.4±0.4 ≤0.001*	0.516
FBG (mg/dL) Mean±SD P value	-14.5±25.0 0.029*	-18.2±32.5 0.034*	-26.2±33.0 0.005*	-34.1±15.8 ≤0.001*	0.174
PPBG (mg/dL) Mean±SD P value	-28.6±31.3 0.002*	-28.5±40.7 0.011*	-38.9±39.3 ≤0.001*	-59.4±40.9 ≤0.001*	0.071
HbA1c Mean±SD P value	-0.4±0.4a 0.002*	-0.4±0.7a 0.028*	-0.7±0.7ab 0.002*	-1.1±0.7b ≤0.001*	0.006*
ALT (IU/mL) Mean±SD P value	0.2±5.4 0.894	0.1±6.2 0.939	0.2±5.1 0.887	-2.2±4.5 0.056	0.466
AST (IU/mL) Mean±SD P value	0.3±4.5 0.791	0.2±5.4 0.860	0.4±3.9 0.711	-0.4±5.1 0.746	0.963
Creatinine (mg/dl) Mean±SD P value	-0.3±0.7 0.894	-0.4±0.5 0.490	-0.4±0.7 0.400	-0.5±0.4 0.346	0.720
Uric acid(mg/dl) Mean±SD P value	-0.3±0.7 0.139	-0.4±0.5 0.005*	-0.4±0.7 0.032*	-0.5±0.4 ≤0.001*	0.720
Cholesterol (mg/dL) Mean±SD P value	-14.1±17.8a 0.005*	-29.4±23.0ab ≤0.001*	-35.6±41.3ab 0.003*	-55.0±53.2b ≤0.001*	0.018*
Triglycerides (mg/dL) Mean±SD P value	-20.9±22.9 0.002*	-24.6±23.1 ≤0.001*	-25.9±42.5 0.020*	-39.4±45.6 0.003*	0.431

Mean difference =6thmonth – baseline (negative values indicate reduction, Paired t-test compare mean difference in each group ^ANOVA test, pylori treatments.

Group-MHD: Cases received medical and anti-H. pylori treatments and dietary regimen.

with post hoc Tukey's test *Significant




Fig.2. Comparison between the studied groups regarding HbA1c reduction.




Fig.3. Comparison between the studied groups regarding cholesterol change.

Discussion

Chronic infection with *H. pylori* can cause serious complications on stomach. Recent studies have linked between *H. pylori* infection and incidence of various illnesses. *H. pylori* is believed to have a bad effect on glycemic state in diabetic patients. Our study aimed to assess the efficacy of diet control and *H. pylori* eradication therapy on the glycemic control of the patients.

Eighty five diabetic patients divided into equal four groups. The four groups were homogenous and showed no statistical difference in baseline characteristics. Our study showed that both diet control and anti *H. pylori* therapy causes a decrease in the body mass index of all study participants which could be referred to the proper lifestyle measures that was followed during the study. On the other hand Xu et al, Azuma et al. and Choi et al. have all concluded that BMI increases after *H. pylori* eradication on both children and adults. They referred that to termination of annoying symptoms of epigastric pain and reflux which encourage the patients to eat larger quantities. But all these studies rely on eradication therapy only without making a proper supplementary nutrition plan for study participants.

Eradication of *H. pylori* as well as diet therapy have aided in proper glycemic control of patients of all groups except group M which showed poor reduction in Fasting, post prandial and glycosylated hemoglobin values. Group MHD showed the best results denoting the beneficial synergetic effect of diet control and *H. pylori* eradication on glycemic state. Zojaji et al also stated that *H. pylori* eradication aids in improvement of glycemic state of patients. Dai et al revealed the association of *H. pylori* infection and poor glycemic control however they didn't confirm any beneficial role of *H. pylori* eradication. On the other hand Horikawa et al and Candelli et al have concluded the *H. pylori* eradication has no role in improving the glycemic state of diabetic patients.

There was no statistical changes in liver transaminases in all groups. While Salehi et al results revealed the beneficial role of *H. pylori* eradication on lowering the unexplained high liver transaminases. Non significant changes in the current study because all patients had normal baseline liver transaminases.

Many studies discussed the relation of *H. pylori* and dyslipidemia (Kim, et al., 2011).

Also high cholesterol level can aid in *H. pylori* resistant (McGee et al., 2011), however – up to our knowledge – No study has discussed the role of eradication on cholesterol levels. Our study results showed statistical reduction in total cholesterol and triglycerides in each study at 6th month than baseline.

H. pylori eradication has no effect on creatinine levels and this comes in agreement with results of Bahar Caliskan et al study which deny any role of *H. pylori* eradication on creatinine levels (Caliskan et al., 2014). Moreover our study was – up to our knowledge – the first one to discuss *H. pylori* eradication effect on uric acid levels which was significantly improved after eradication in each of intervention study groups.

Conclusion

After enrolment of 68 patients meeting the inclusion criteria and their random equal distribution among 4 groups it was noticed that FBG, PPBG and HbA1c significantly decreased in all groups, however the best reduction was intervention group received both anti *H. pylori* and strict diet regimen. BMI significantly decreased in all groups except group-M., ALT, AST and serum creatinine non-significantly changed in all groups, Cholesterol and triglycerides significantly decreased in all groups while Uric acid significantly decreased in all groups except group-M.

According to the above results, the combined regimen that include (medical treatment + Anti *H. pylori* + Diet control) shows a promising effect on the glycemic control and lipid profile of type II Diabetic patients under insulin therapy.

References

- Horiki N, Omata F, Uemura M, et al. Annual change of primary resistance to clarithromycin among *Helicobacter pylori* isolates from 1996 through 2008 in Japan. *Helicobacter*. 2009 Oct. 14(5):86-90. [Medline].
- Fallone CA. Epidemiology of the antibiotic resistance of *Helicobacter pylori* in Canada. *Can J Gastroenterol*. 2000 Nov. 14(10):879-82.
- Hsu PI, Wu DC, Chen WC, et al. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for *Helicobacter pylori* infection. *Antimicrob Agents Chemother*. 2014 Oct. 58 (10):5936-42.

- Paziak-Domańska B, Chmiela M, Jarosińska A, Rudnicka W. Potential role of CagA in the inhibition of T cell reactivity in Helicobacter pylori infections. *Cell Immunol.* 2000;202:136–139.
- Bruwer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, Nusrat A. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. *J Immunol.* 2003;171:6164–6172.
- Papagiannakis P, Michalopoulos C, Papalexi F, Dalampoura D, Diamantidis MD. The role of Helicobacter pylori infection in hematological disorders. *Eur J Intern Med.* 2013;24:685–690
- El-Eshmawy MM, El-Hawary AK, Abdel Gawad SS, El-Baiomy AA. Helicobacter pylori infection might be responsible for the interconnection between type 1 diabetes and autoimmune thyroiditis. *Diabetol Metab Syndr.* 2011;3:28.
- Xu M-Y, Liu L, Yuan B-S, Yin J, Lu Q-B. Association of obesity with Helicobacter pylori infection: A retrospective study. *World Journal of Gastroenterology.* 2017; 23(15):2750-2756. doi:10.3748/wjg.v23.i15.2750.
- Azuma T1, Suto H, Ito Y, Muramatsu A, Ohtani M, Dojo M, Yamazaki Y, Kuriyama M, Kato T. Eradication of Helicobacter pylori infection induces an increase in body mass index. *Aliment Pharmacol Ther.* 2002 Apr; 16 Suppl 2:240-4.
- Choi JS, Ko KO, Lim JW, Cheon EJ, Lee GM, Yoon JM. The Association between Helicobacter pylori Infection and Body Weight among Children. *Pediatric Gastroenterology, Hepatology & Nutrition.* 2016; 19(2):110-115. doi:10.5223/pghn.2016.19.2.110.
- Zojaji H, Ataei E, Sherafat SJ, Ghobakhlou M, Fatemi SR. The effect of the treatment of Helicobacter pylori infection on the glycemic control in type 2 diabetes mellitus. *Gastroenterology and Hepatology from Bed to Bench.* 2013; 6(1):36-40.
- Dai Y-N, Yu W-L, Zhu H-T, Ding J-X, Yu C-H, Li Y-M. Is Helicobacter pylori infection associated with glycemic control in diabetics? *World Journal of Gastroenterology : WJG.* 2015; 21(17):5407-5416. doi:10.3748/wjg.v21.i17.5407.
- Horikawa C, Kodama S, Fujihara K, et al. Association of Helicobacter pylori Infection with Glycemic Control in Patients with Diabetes: A Meta-Analysis. *Journal of Diabetes Research.* 2014; 2014:250620. doi:10.1155/2014/250620.
- Westat, Inc. Body Measurements (Anthropometry) In National Health And Nutrition Examination Survey III, (<https://wwwn.cdc.gov/nchs/data/nhanes3/manuals/anthro.pdf>), 1988.
- Candelli M, Rigante D, Marietti G, Nista EC, Crea F, Schiavino A, Cammarota G, Pignataro G, Petrucci S, Gasbarrini G, Gasbarrini A. Helicobacter pylori eradication rate and glycemic control in young patients with type 1 diabetes. *J Pediatr Gastroenterol Nutr.* 2004 Apr; 38(4) 422-425. Doi: 10.1097/00005176-200404000-00010. PMID: 15085021.
- Salehi H, Minakari M, Yaghoutkar A, Tabesh E, Salehi M, Mirbagher L. The effect of Helicobacter pylori eradication on liver enzymes in patients referring with unexplained hypertransaminasemia. *Advanced Biomedical Research.* 2014; 3:131. doi:10.4103/2277-9175.133256.
- Kim H-L, Jeon HH, Park IY, Choi JM, Kang JS, Min K-W. Helicobacter pylori Infection is associated with Elevated Low Density Lipoprotein Cholesterol Levels in Elderly Koreans. *Journal of Korean Medical Science.* 2011; 26(5):654-658. doi:10.3346/jkms.2011.26.5.654.
- McGee DJ, George AE, Trainor EA, Horton KE, Hildebrandt E, Testerman TL. Cholesterol Enhances Helicobacter pylori Resistance to Antibiotics and LL-37. *Antimicrobial Agents and Chemotherapy.* 2011; 55(6):2897-2904. doi:10.1128/AAC.00016-11.
- Caliskan B, Yazici H, Caliskan Y, et al. “The Effects of Helicobacter pylori Eradication on Proteinuria in Patients with Primary Glomerulonephritis,” *International Journal of Nephrology*, vol. 2014, Article ID 180690, 6 pages, 2014. <https://doi.org/10.1155/2014/180690>.
- American Diabetes Association. Eating patterns and meal planning. <http://www.diabetes.org/food-and-fitness/food/planning-meals/diabetes-meal-plans-and-a-healthy-diet.html>. Jan. 29, 2019.